Drug Trial Radar · NCT07220252
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Jan 1, 2030
Study completion Jun 30, 2033
Sponsor
- Lead sponsor
- TG Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of ublituximab in participants ages 10 to less than (\<)18 years and body weight greater than or equal to (≥)25 kilograms (kg) to less than or equal to (≤)40 kg with RMS (Part A) and to evaluate the non-inferiority of ublituximab compared with fingolimod in pediatric RMS participants with body weight ≥ 25 kg (Part B). The study will further evaluate long-term safety and efficacy of ublituximab in RMS in pediatric participants during its extension period (Part C).
Conditions
- Relapsing Multiple Sclerosis
Interventions
UblituximabDrug
Administered as an intravenous (IV) infusion.
PlaceboDrug
Oral capsule.
PlaceboDrug
IV infusion.
FingolimodDrug
Oral capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Area Under the Curve From Week 0 to 24 (AUC0-W24) of UblituximabTime frame: Predose and multiple timepoints up to Week 24
- Part A: Maximum Observed Concentration (Cmax) of UblituximabTime frame: Day 1 and Day 15
- Part A: Participant B Cell CountsTime frame: Up to Week 24
- Part B: Annualized Relapse Rate (ARR)Time frame: Up to 96 weeks
- Part C: Annualized Relapse Rate (ARR)Time frame: Up to 168 weeks
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
TG Therapeutics Investigational Trial Site
Salt Lake City, Utah · Recruiting
TG Therapeutics Investigational Trial Site
Gdansk, Poland · Recruiting
TG Therapeutics Investigational Trial Site
Poznan, Poland · Not yet recruiting
TG Therapeutics Investigational Trial Site
Rzeszów, Poland · Recruiting
TG Therapeutics Investigational Trial Site
Warsaw, Poland · Recruiting
TG Therapeutics Investigational Trial Site
Bratislava, Slovakia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.